# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $38 p...
JMP Securities analyst Jonathan Wolleben reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and main...
JNJ-2113 was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist ...
JP Morgan analyst Brian Cheng maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target...
HC Wainwright & Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $38 ...
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate...